The Increasing Prevalence Of Epilepsy Is Fueling The Growth Of The Market Due To Rising Cases Driven By An Aging Population And The Need For Effective Seizure Control Is Supporting Development Across The Gabapentin Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Size Is Forecasted For The Gabapentin Market By 2030 Based On Its 2026 Value?

The gabapentin market size has experienced significant expansion in recent years. It is projected to rise from $3.01 billion in 2025 to $3.26 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.4%. The growth observed in the past can be attributed to the adoption of epilepsy treatments, the prevalence of neuropathic pain, the availability of generic drugs, physician prescribing patterns, and the increasing burden of chronic diseases.

The gabapentin market is anticipated to experience substantial expansion over the coming years. Its valuation is projected to reach $4.45 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.1%. This projected growth during the forecast period is due to factors such as an aging population, the rise in diabetic neuropathy, increased generic drug penetration, outpatient pain management strategies, and the widespread adoption of telemedicine prescriptions. Key trends influencing this period encompass the growing application in neuropathic pain management, a heightened demand for generic versions, the broadening of chronic pain treatment initiatives, the increasing prevalence of oral solid dosage forms, and a surge in prescriptions for various neurological conditions.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24544&type=smp

Which Growth Drivers Are Expected To Support The Gabapentin Market Forward?

The expanding occurrence of epilepsy is projected to fuel the expansion of the gabapentin market in the foreseeable future. Epilepsy, a neurological condition, manifests as recurrent seizures stemming from erratic electrical signals within the brain. The rise in epilepsy instances primarily correlates with the expanding elderly demographic, given that advancing age heightens the susceptibility to neurological conditions capable of inducing seizures. Gabapentin manages epilepsy by moderating atypical nerve impulses in the brain and diminishing signals that trigger seizures. Its mechanism involves targeting calcium channels, thereby assisting in the prevention of seizure episodes. As an illustration, data from February 2024 provided by the World Health Organization (WHO), a Switzerland-intergovernmental organization, indicates that approximately 50 million individuals worldwide suffer from epilepsy, with almost 80% residing in low- and middle-income countries, and potentially 70% could achieve a seizure-free life through accurate diagnosis and appropriate treatment. Annually, an estimated 5 million individuals receive a new epilepsy diagnosis globally; specifically, in high-income countries, this rate stands at approximately 49 per 100,000, whereas in low- and middle-income countries, it may reach up to 139 per 100,000. Consequently, the rising incidence of epilepsy is propelling the expansion of the gabapentin market.

How Is Segment Classification Applied In The Gabapentin Market?

The gabapentin market covered in this report is segmented –

1) By Type: Generic, Branded

2) By Dosage Form: Tablet, Capsule, Oral Solution

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

4) By Application: Epilepsy, Neuropathic Pain, Restless Legs Syndrome, Other Applications

Subsegments:

1) By Generic: Gabapentin Immediate Release (IR), Gabapentin Extended Release (ER), Gabapentin Capsules, Gabapentin Tablets, Gabapentin Oral Solution

2) By Branded: Neurontin, Gralise, Horizant, Other Branded Formulations

What Trends Are Impacting The Gabapentin Market?

Leading companies in the gabapentin market are prioritizing the creation of advanced formulations, specifically bioequivalent tablets, to improve therapeutic effectiveness and broaden treatment avenues for neurological disorders. These bioequivalent tablets are generic medications designed to deliver the same dosage of their active component into the bloodstream at an equivalent rate and efficiency as their branded counterparts, thereby ensuring comparable safety and therapeutic outcomes. An example of this is the launch by Strides Pharma Science Limited, an India-based pharmaceutical company, in March 2024, of Gabapentin Tablets USP in 600 mg and 800 mg strengths. This product received approval from the United States Food & Drug Administration (USFDA) to further extend its neurology offerings in the US market. This innovative gabapentin formulation offers increased bioavailability, accurate dosing, and ease of administration for patients, leading to more predictable therapeutic results, better management of symptoms, and enhanced convenience for ongoing treatment. Specifically, Gabapentin tablets USP, 600 mg, demonstrate broad therapeutic utility, enabling the effective treatment of various neurological conditions, including neuropathic pain and partial seizures, supported by dependable dosing and established clinical effectiveness.

Which Organizations Are Involved In The Gabapentin Market?

Major companies operating in the gabapentin market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan Inc., Apotex Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Lupin Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Ltd., Ipca Laboratories Private Limited, Granules India Limited, Medley Pharmaceuticals Limited, Wockhardt Limited, Epic Pharma LLC, Healing Pharma India Pvt. Ltd., Rochem International Inc., Accord Healthcare Limited, Strides Pharma Science Limited, Ascend Laboratories LLC

Access The Complete Gabapentin Market Report:

https://www.thebusinessresearchcompany.com/report/gabapentin-global-market-report

Which Region Is The Primary Market For The Gabapentin Market?

North America was the largest region in the gabapentin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gabapentin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Gabapentin Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24544&type=smp

Browse Through More Reports Similar to the Global Gabapentin Market 2026, By The Business Research Company

Glycomic Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/glycomic-therapeutics-global-market-report

Glycopeptide Antibiotics Market Report 2026

https://www.thebusinessresearchcompany.com/report/glycopeptide-antibiotics-global-market-report

Antiglaucoma Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/antiglaucoma-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795